Legend Biotech PE Ratio 2019-2021 | LEGN

Current and historical p/e ratio for Legend Biotech (LEGN) from 2019 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Legend Biotech PE ratio as of May 27, 2022 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Legend Biotech PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2022-05-27 42.73 0.00
2021-12-31 46.61 $-1.36 0.00
2021-09-30 50.56 $-1.28 0.00
2021-06-30 41.05 $-1.10 0.00
2021-03-31 29.02 $-1.40 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.069B $0.090B
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in Cayman Islands.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00